DOCSLIB.ORG

Drug-Related Deaths in Scotland in 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug-Related Deaths in Scotland in 2019 Drug-related deaths in Scotland in 2019 Published on 15 December 2020 Statistics of drug-related deaths in 2019 and earlier years, broken down by age, sex, selected drugs reported, underlying cause of death and NHS Board and Council areas. Drug-related deaths in Scotland, 2019 Summary Drug-related deaths Drug-related deaths, 1996 to 2019 continue to increase 1,264 The number of drug-related The dashed line shows the 5-year moving average and the shaded area deaths has increased almost shows the likely range of variation every year. In 2019 there around the 5-year moving average. were 1,264, which is the largest number ever recorded and more than 527 double the number recorded a decade ago. 244 1996 2013 2019 Largest increase was in Drug-related death rates by age group, 2000 to 2019 35-54 year olds 15-24 25-34 35-44 45-54 55-64 Most of the increase in drug related death rates* has 0.6 occurred in the 35-44 year old and 45-54 year old age 0.4 groups. 0.2 0.0 * Deaths per 1,000 people 2000 2019 2000 2019 2000 2019 2000 2019 2000 2019 Death rates vary Drug-related death rates by health board, 2015 to 2019 geographically Greater Glasgow & Clyde 0.27 Tayside 0.21 Greater Glasgow & Clyde Ayrshire & Arran 0.20 had the highest rate* at 0.27 Scotland 0.18 per 1,000 population, Lanarkshire 0.18 Forth Valley 0.17 followed by Tayside and Fife 0.16 Ayrshire & Arran with rates Lothian 0.15 of 0.21 and 0.20 per 1,000 Dumfries & Galloway 0.14 Grampian 0.14 population respectively. Borders 0.13 Highland 0.10 Orkney 0.06 * Rates are based on 5-year averages to Shetland 0.05 reduce year-to-year fluctuations. Western Isles 0.05 www.nrscotland.gov.uk Source: Drug-related deaths in Scotland, 2019 Key Points 1,264 drug-related deaths were registered in Scotland in 2019, 6% (77) more than in 2018. This was the largest number ever recorded, and more than double that of ten years earlier (545 in 2009). Males accounted for 69% of the drug-related deaths in 2019, a similar proportion to recent years. The median age of drug-related deaths has increased from 28 to 42 over the last 20 years. In 2019, over two-thirds (68%) of all drug-related deaths were of people aged between 35 and 54: there were 856 such deaths, 69 more than in 2018. There was also an increase in 15-24 year old drug-related deaths, from 64 in 2018 to 76 in 2019. Three-quarters of all drug-related deaths were in the following five Health Board areas: Greater Glasgow & Clyde (404), Lanarkshire (163), Lothian (155), Tayside (118) and Ayrshire & Arran (108). Together, they accounted for a slightly higher proportion of the total than in most of the previous ten years. The Health Board areas with the largest increases over the last decade (using a five year average) were Greater Glasgow & Clyde (up by 152), Lothian (up 67), Lanarkshire (up 66), Tayside (up 52) and Ayrshire & Arran (up 45). Scotland’s drug-death rate was higher than those reported for all the EU countries, and was approximately 3½ times that of the UK as a whole. Of the 1,264 drug-related deaths in 2019, these substances were implicated in, or potentially contributed to the cause of, the following numbers of deaths: - heroin and/or morphine 645 deaths, more than in any previous year and 51% of the total; - methadone 560 deaths, the same as in 2018 (44%); - one or more opiates or opioids (including heroin/morphine and methadone) 1,092 deaths, more than in any previous year (86%); - ‘street’ benzodiazepines (such as etizolam) 814 deaths, more than in any previous year (64%) - ‘prescribable’ benzodiazepines (such as diazepam) 195 deaths, fewer than in 2017 and 2018 (15%) - gabapentin and/or pregabalin 438 deaths, more than in any previous year (35%); - cocaine 365 deaths, more than in any previous year (29%). 94% of all drug-related deaths were of people who took more than one substance. 3 © Crown Copyright 2020 Contents List of Tables ..................................................................................................................... 5 List of Figures ................................................................................................................... 6 Summary. ........................................................................................................................... 7 1. Introduction ....................................................................................................... 10 2. Data sources ..................................................................................................... 11 3. Drug-related deaths: trends, causes of death, drugs reported, sex and age .... 14 3.1 Overall numbers .................................................................................................. 14 3.2 Underlying causes of death ................................................................................. 16 3.3 Selected drugs reported ...................................................................................... 17 3.4 Sex and age ........................................................................................................ 21 3.5 Death rates for problem drug users ..................................................................... 24 4. NHS Board areas: trends, causes, drugs reported, and death rates by age- group and relative to the estimated number of problem drug users .................. 25 5. Council areas (trends, causes, drugs reported and death rates by age-group) and areas with smaller populations ................................................................... 28 Annex A: The definition of drug-related deaths used for these statistics (the National Records of Scotland (NRS) implementation of the ‘baseline’ definition for the UK Drugs Strategy) ........................................................................................... 30 Annex B: Some other definitions of drug-related deaths ................................................... 35 Annex C: References ....................................................................................................... 40 Annex D: The questionnaire used to obtain further information about drug-related deaths, with effect from 2014 ......................................................................................... 41 Annex E: So-called ‘New Psychoactive Substances’ ........................................................ 42 Annex F: A consistent series of drug-related death numbers, based on the classification at the end of the latest year covered by the publication .................................... 46 Annex G: Drug-related Deaths – comparison with other countries ................................... 49 Annex H: ‘Prescribable’ and ‘street’ benzodiazepines ...................................................... 53 6. Notes on statistical publications ........................................................................ 86 7. Related organisations ....................................................................................... 88 4 © Crown Copyright 2020 List of Tables Table 1: Drug-related deaths in Scotland, 1996 – 2019 .......................................... 55 Table 2: Drug-related deaths by underlying cause of death1, Scotland, 1996 – 2019 56 Table 3: Drug-related deaths by selected drugs reported1, Scotland, 1996 – 2019 57 Table 4: Drug-related deaths by sex and age, Scotland, 1996 – 2019 ................... 58 Table 5: Drug-related deaths by sex, age and underlying cause of death1, Scotland, 2019 .......................................................................................................... 59 Table 6: Drug-related deaths by sex, age and selected drugs reported1, Scotland, 2019 .......................................................................................................... 60 Table 7: Drug-related deaths involving only one drug by sex, age and selected drugs reported1, Scotland, 2019 .......................................................................... 61 Table 8: Drug-related deaths per 1,000 population, Scotland, 2000 to 2019 .......... 62 Table 9: Drug-related deaths by sex and age-group: average for 2013 to 2017, and relative to the estimated number of problem drug users in 2015/16 .......... 63 Table HB1: Drug-related deaths by NHS Board area, 2009 - 2019 (with averages for 2005-2009 and 2015-2019) ....................................................................... 64 Table HB2: Drug-related deaths by underlying cause of death1 and NHS Board area, 2019 .......................................................................................................... 65 Table HB3: Drug-related deaths by selected drugs reported1 and NHS Board area, 2019 .......................................................................................................... 66 Table HB4: Drug-related deaths per 1,000 population, NHS Board areas, annual averages for 2015 to 2019 1 ...................................................................... 67 Table HB5: Drug-related deaths by NHS Board area: average for 2013 to 2017, and relative to the estimated number of problem drug users in 2015/16 .......... 68 Table C1: Drug-related deaths by council area, 2009 - 2019 (with averages for 2005- 2009 and 2015-2019) ................................................................................ 70 Table C2: Drug-related deaths by underlying cause1 and council area, 2019 ........... 71 Table C3: Drug-related deaths by selected drugs reported1 and council area, 2019 . 72 Table C4: Drug-related deaths per 1,000 population, council areas, annual
Load more

Recommended publications
  • Test Update Immediate Action Notification
    Effective Date: Monday, April 27, 2020 Test Updates Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, April 27, 2020 Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Discontinued Tests - Tests being discontinued with alternate testing suggestions. Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases. If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document. NMS Labs 200 Welsh Rd. Horsham, PA 19044-2208 [email protected] Page 1 of 6 Effective Date: Monday, April 27, 2020 Test Updates Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments Designer Benzodiazepines (Qualitative), 0570U • Urine (Forensic) Designer Benzodiazepines Confirmation 52487U • (Qualitative), Urine Designer Benzodiazepines Confirmation, 52487B • Blood Designer Benzodiazepines Confirmation, 52487SP • Serum/Plasma Designer Benzodiazepines, Blood 0570B • (Forensic) Designer Benzodiazepines, 0570SP • Serum/Plasma (Forensic) NMS Labs 200 Welsh Rd.
    [Show full text]
  • 2016-08-Issue 3
    u e n mb u e s r s i ∙ ∙ 3 2 0 1 6 new products! Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org. No.: NO 967 607 657 MVA NEW PRODUCTS Issue No. 3 Toxicology Chiron Cat. No. Name (Synonym) CAS No. Antibiotics 11624.12 Albendazole 54965-21-8 11623.16 Amoxicillin trihydrate 61336-70-7 11634.16 Ampicillin 69-53-4 11629.38 Azithromycin dihydrate 117772-70-0 11633.2 Cefuroxime axetil 64544-07-6 11613.13 Ciprofloxacin HCl Imp. A 86393-33-1 (7-​Chloro-​1-​cyclopropyl-​6-​fluoro-​1,​4-​dihydro-​4-​oxo-​quinoline-​3-​carboxylic acid) 11614.19 Enrofloxacin, 98% 93106-60-6 Antidepressants 11631.20 (S)-Citalopram oxalate 219861-08-2 (Escitalopram oxalate) 11641.23 Opipramol 315-72-0 11500.21 Tianeptine sulphate mono hydrate 30123-17-2 (anhydrous) Benzodiazepines 11409.15 Desalkylflurazepam 2886-65-9 11507.17 Flunitrazolam N/A 11506.17 Nitrazolam 28910-99-8 11788.16 Tetrazepam 10379-14-3 Cardic Drugs 11632.25 Irbesartan 138402-11-6 11618.24 Spironolactone 52-01-7 11630.24 Valsartan 137862-53-4 Catecholamines 11651.8 Dopamine hydrochloride 62-31-7 11648.9 Epinephrine hydrochloride 329-63-5 11653.1 5-Hydroxyindole-3-acetic acid 54-16-0 (5-HIAA) 11646.1 Metanephrine hydrochloride 881-95-8 11650.9 3-Methoxytyramine hydrochloride 1477-68-5 (3-MT HCl) 11649.8 Norepinephrine hydrochloride 55-27-6 11647.9 Normetanephrine hydrochloride 1011-74-1 Cathinones 11491.14 N,N-Dimethylpentylone hydrochloride 17763-13-2 (bk-DMBDP HCl, Dipentylone HCl) 11640.14 N-Ethylhexedrone hydrochloride 18410-62-3 (HEX-EN) 11492.14 N-Ethylpentylone hydrochloride 17763-02-9 11800.11 Methedrone hydrochloride 879665-92-6 (para-methoxymethcathinone, 4-methoxymethcathinone, bk-PMMA, PMMC, methoxyphedrine, 4-MeOMC) 11487.19 TH-PVP N/A Chiron AS Stiklestadvn.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Flualprazolam Sample Type: Biological Fluid
    Flualprazolam Sample Type: Biological Fluid Latest Revision: June 25, 2019 Date of Report: June 25, 2019 1. GENERAL INFORMATION IUPAC Name: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine InChI String: InChI=1S/C17H12ClFN4/c1-10-21-22-16-9-20-17(12-4-2-3-5- 14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3 CFR: Not Scheduled (06/2019) CAS# 28910-91-0 Synonyms: 2’-Fluoro Alprazolam, ortho-Fluoro Alprazolam Source: NMS Labs – Toxicology Department 2. CHEMICAL DATA Chemical Molecular Molecular Exact Mass Analyte Formula Weight Ion (M) [M+H]+ Flualprazolam C17H12ClFN4 326.75 326 327.0807 Important Note: All identifications were made based on evaluation of analytical data (LC-QTOF) in comparison to analysis of acquired reference material. Report Prepared By: Alex J. Krotulski, MSFS, and Barry K. Logan, PhD, F-ABFT 3. SAMPLE HISTORY Flualprazolam has been identified in three cases since March 2018. The geographical and demographic breakdown is below: Geographical Location: Pennsylvania (n=2), Indiana (n=1) Biological Sample: Blood (n=3) Date of First: Collection: March 8, 2018 Receipt: March 10, 2018 Date of Most Recent: Collection: June 3, 2019 Receipt: June 7, 2019 Additional NPS: Etizolam (n=2), Clonazolam (n=1), Flubromazolam (n=1) 4. BRIEF DESCRIPTION Flualprazolam is classified as a novel benzodiazepine, although its synthesis and activity have been previously described in the literature.1 Benzodiazepines are central nervous system depressants. Novel benzodiazepines, often pirated from early drug discovery or pharmaceutical studies, have appeared on novel and illicit drug markets in recent years.
    [Show full text]
  • 1 'New/Designer Benzodiazepines'
    1 ‘New/Designer Benzodiazepines’: an analysis of the literature and psychonauts’ trip reports 2 Laura Orsolini*1,2,3, John M. Corkery1, Stefania Chiappini1, Amira Guirguis1, Alessandro Vento4,5,6,7, 3 Domenico De Berardis3,8,9, Duccio Papanti1, and Fabrizio Schifano1 4 5 1 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical 6 Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK. 7 2 Neomesia Mental Health, Villa Jolanda Hospital, Jesi, Italy. 8 3 Polyedra, Teramo, Italy. 9 4 NESMOS Department (Neurosciences, Mental Health and Sensory Organs), Sapienza University – Rome, School of 10 Medicine and Psychology; Sant’Andrea Hospital, Rome, Italy 11 5 School of psychology - G. Marconi Telematic University, Rome, Italy 12 6 Addictions Observatory (ODDPSS), Rome, Italy 13 7 Mental Health Department - ASL Roma 2, Rome, Italy 14 8 Department of Neuroscience, Imaging and Clinical Science, Chair of Psychiatry, University of “G. D’Annunzio”, Chieti, 15 Italy. 16 9 NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4 17 Teramo, Italy. 18 19 Corresponding author: 20 Laura Orsolini, Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life 21 and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK; Villa Jolanda Hospital, Neomesia 22 Mental Health, Villa Jolanda, Italy; Polyedra, Teramo, Italy; E-mail address: [email protected]. Tel.: (+39) 392 23 3244643. 24 25 Conflicts of Interest 26 The authors declare that this research was conducted in the absence of any commercial or financial relationships 27 that could be construed as a potential conflict of interest.
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]
  • Förordning Om Ändring I Förordningen (1992:1554) Om Kontroll Av Narkotika;
    Príloha 11 k rozhodnutiu švédskych úradov vlády 22. februára 2018 § 79 1. ------IND- 2018 0079 S-- SK- ------ 20180302 --- --- PROJET Zbierka zákonov Švédska SFS Published on issued on 1 March 2018. The government hereby lays down1 that Annex 1 to the Ordinance (1992:1554) on the control of narcotic drugs2 shall read as set out below. This ordinance shall enter into force on 10 April 2018. On behalf of the Government ANNIKA STRANDHÄLL Lars Hedengran (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Ordinance reprinted as 1993:784. 1 SFS Annex 13 List of substances to be considered narcotic drugs according to the Narcotic Drugs Punishments Act Stimulants of the central nervous system ethylamphetamine (2-ethylamino-1-phenylpropane) fenethylline [1-phenyl-1-piperidyl-(2)-methyl]acetate 1-phenyl-2-butylamine N-hydroxyamphetamine propylhexedrine 4-methylthioamphetamine (4-MTA) modafinil 4-methoxy-N-methylamphetamine (PMMA, 4-MMA) 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) 4-iodo-2,5-dimethoxyphenethylamine (2C-I) 2,4,5-trimethoxyamphetamine (TMA-2) 4-methylmethcathinone (mephedrone) 4-fluoramphetamine 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one (methedrone) 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-one (MDPV) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
    [Show full text]
  • Bioanalytical Studies of Designer Benzodiazepines
    From DEPARTMENT OF LABORATORY MEDICINE Karolinska Institutet, Stockholm, Sweden BIOANALYTICAL STUDIES OF DESIGNER BENZODIAZEPINES Madeleine Pettersson Bergstrand Stockholm 2018 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Eprint AB © Madeleine Pettersson Bergstrand, 2018 ISBN 978-91-7831-063-0 Front page illustration: Sandra Eriksson Bioanalytical studies of designer benzodiazepines THESIS FOR DOCTORAL DEGREE (Ph.D.) The thesis will be defended at 4X, Alfred Nobels allé 8, Huddinge Friday, May 25, 2018 at 09.00 a.m. By Madeleine Pettersson Bergstrand Principal Supervisor: Opponent: Prof. Anders Helander Ass. Prof. Elisabeth Leere Øiestad Karolinska Institutet Oslo University Hospital Department of Laboratory Medicine Department of Forensic Sciences Division of Clinical Chemistry Clinic for Laboratory medicine Co-supervisor: Examination Board: Prof. Olof Beck Prof. Åsa Emmer Karolinska Institutet KTH Royal Institute of Technology Department of Laboratory Medicine Department of Chemistry Division of Clinical Pharmacology Division of Applied Physical Chemistry Docent Stefan Borg Karolinska Institutet Department of Clinical Neuroscience Docent Pierre Lafolie Karolinska Institutet Department of Medicine Division of Clinical Epidemiology ABSTRACT The fast appearance of benzodiazepine analogues, referred to as new psychoactive substance (NPS) or designer benzodiazepines, requires the continuous update of detection methods in order to keep up with the latest drugs on the recreational drug market. Moreover, as usually only limited information on toxicity and excretion patterns of these new drugs exists, this needs to be evaluated to report on adverse effects and to determine suitable targets for drug testing. Urine drug testing usually involves screening using immunoassay followed by confirmation of positive screening results using mass spectrometric (MS) methods.
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • Infographics About Synthetic Opioids
    UNODC LEADING THE INTERGRATED GLOBAL RESPONSE TO THE OPIOID CRISIS P I L L A R 1 P I L L A R 2 P I L L A R 3 P I L L A R 4 P I L L A R 5 I N T E R N A T I O N A L L A W S T R E N G T H E N I N G C O U N T E R E A R L Y W A R N I N G A N D R A T I O N A L P R E S C R I B I N G A N D S T R E N G T H E N I N G A N D S U P P O R T I N G E N F O R C E M E N T O P E R A T I O N S N A R C O T I C C A P A C I T Y A N D T R E N D A N A L Y S I S A C C E S S T O O P I O I D S P R E V E N T I O N A N D T R E A T M E N T T O D I S R U P T T R A F F I C K I N G I N T E R N A T I O N A L C O O P E R A T I O N IDENTIFYING THE MOST PREVELANT, PERSISTANT AND HARMFUL SYNTHETIC OPIOIDS U N O D C 282 90 E A R L Y TOXICOLOGY COLLABORATING IN COUNTRIES W A R N I N G INFORMED THREATS LABORATORIES A D V I S O R Y ASSESSMENTS PHARMACOLOGICAL INFORMATION L A B O R A T O R I E S A N D D A T A P O I N T S L A B O R A T O R I E S D A T A P O I N T S G L O B A L S M A R T U P D A T E S 21,400+ 120 DATA POINTS FROM COUNTRIES SYNTHETIC SEDATIVE 74 OPIOIDS HYPNOTICS REPORTED MIRRORING TO UNODC SYNTHETIC E A R L Y OPIOID TRENDS W A R N I N G A D V I S O R Y B Y 2019 131% IN THE LAST * * 3 Y E A R S Note: * 2019 data collection not finalized LIST OF SYNTHETIC OPIOIDS REPORTED TO THE UNODC EWA FROM 2009-2019 S C H E D U L E D 2-Fluorofentanyl Furanylfentanyl 4-Fluorobutyrfentanyl Methoxyacetylfentanyl 4-Fluoroisobutyrfentanyl MT-45 S C H E D U L E I Acrylfentanyl Ocfentanil ( 1 9 6 1 ) AH-7921 Tetrahydrofuranylfentanyl Butyrfentanyl U-47700 S C H E D U L E I & I V Cyclopropylfentanyl
    [Show full text]
  • New Psychoactive Substances & Patterns of Use in Detention Settings
    New psychoactive substances & patterns of use in detention settings Robert Teltzrow, Principal Project Consultant, Pompidou Group, Council of Europe 19. February 2020, Republic Event Hall Content of Presentation 1. Definition of NPS 2. Prevalence of NPS in prison 3. Effects and harms of NPS 4. Responses to NPS use in prison 5. Conclusions and discussion 2 Defining NPS Types of classifications • Chemical similarities • Source of the substance (synthetic or plant) • Uses (medicinal or recreational) • Legal definitions (legal/illegal/decriminalised) • Effects on the mind and body (the specific effect on the central nervous system) 4 Effects on mind and body • Caffeine • Alcohol • Nicotine • Opiates • Amphetamines • Cannabis • Ecstasy • Sedatives Depressants Stimulants • Cocaine • Glues, solvents Hallucinogens • Ecstasy • Mescaline • LSD • High doses of cannabis • Psilocybin / Magic Mushrooms 5 Drug Wheel includes NPS Drug Wheel, Alcohol and Drug Foundation (ADF), https://adf.org.au/insights/drug-wheel/ 6 Old PS and new-PS / legal highs Traditional psychoactive (illicit) substances New psychoactive (legal) substances Opium Heroin MDMA / XTC JWH-018 Mephedrone Derived from plants, semi-synthetic or synthetic Synthetic 7 Definition NPS NPS are “Narcotic drugs or psychotropic substances made available or used from the early to mid-2000s for their psychoactive properties. Not scheduled or have only been listed since 2015 under the international drug control conventions of 1961 and 1971, and could pose similar threats to public health as do substances scheduled under these conventions. We also focus on synthetic substances rather than those derived from plants.” (Peacock A. et al., The Lancet, 2019) Peacock A. et al.: New psychoactive substances: challenges for drug surveillance, control, and public health responses.
    [Show full text]
  • Targeted LC-MSMS Carboxy-THC (Delta-9) LC/MS/MS for Cannabinoids POS THC (Delta-9) LC/MS/MS for Cannabinoids POS
    Washington State Patrol - Toxicology Laboratory Division This list provides a general overview of analytes that may be tested for by the Toxicology Laboratory, with corresponding method POS: reported as positive only information and estimated expanded uncertainty, where applicable. Note that general screening includes one or a combination of the Day of test: uncertainty calculated following: enzyme multiplied immunoassay (EMIT), basic drug screening by gas chromatography - mass spectrometry/nitrogen on a case-by-case basis phosphorus detection (GC-MS/NPD) and drug screening by liquid chromatography - time of flight mass spectrometry (LC-TOF-MS). Case circumstances may dictate additional screening or targeted analyses, either in-house or by an external laboratory. The Toxicology Laboratory reserves the right to decide which method(s) to use. Please contact the laboratory at 206-262-6100 with any questions. NOTE: Confirmation testing for presumptive positive EMIT results may not be performed, based on case type (e.g., death investigation). Where confirmation testing is not performed, or where confirmation testing is performed and no reportable results are obtained (e.g., < LOQ or ND), the drug/drug class is removed from the EMIT panel description on the Toxicology Test Report. Analyte Name Confirmation Method Name Typical Reporting Limit Expanded Uncertainty Coverage factor Volatiles acetone Headspace GC 10 mg/dL day of test butane Headspace GC/MS POS n/a desflurane Headspace GC/MS POS n/a difluoroethane Headspace GC/MS POS n/a ethanol
    [Show full text]